Business Context and Reporting Period
This Form 8-K was filed by Akebia Therapeutics, Inc. on January 7, 2019. The report discloses a planned presentation at the J.P. Morgan Healthcare Conference and updates regarding the company's recent merger with Keryx Biopharmaceuticals, Inc., completed on December 12, 2018. As of December 31, 2018, the company had 116,887,518 shares of common stock outstanding.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate events and regulatory updates rather than financial performance data.
Material Changes and Corporate Events
- Merger Completion: Keryx Biopharmaceuticals, Inc. became a wholly owned subsidiary of Akebia on December 12, 2018. Keryx shareholders received 0.37433 shares of Akebia common stock for each Keryx share held.
- Product Candidate Update: The Independent Data Monitoring Committee recommended in December 2018 that the global Phase 3 PRO 2 TECT and INNO 2 VATE programs for the product candidate vadadustat continue without modification.
- Patent Litigation: Following Paragraph IV certification notices from generic applicants, Akebia (via Keryx) filed patent infringement lawsuits against Lupin Atlantis Holdings SA and Teva Pharmaceuticals USA, Inc. in December 2018.
Guidance, Outlook, and Risks
Outlook and Contingencies:
- ANDA Stays: The lawsuits against Lupin and Teva triggered 30-month stays on FDA approval of their generic versions of Auryxia (ferric citrate). These stays are expected to remain in effect until April 2021 and May 2021, respectively, absent an earlier court judgment.
- New Generic Challenge: On December 24, 2018, Keryx received a Paragraph IV notice from Chemo Research S.L. regarding a generic Auryxia application. Akebia intends to file a lawsuit within 45 days to trigger a similar 30-month stay.
- Forward-Looking Statements: The company warns that the approval and launch of generic products competing with Auryxia could adversely affect its business, financial position, and results of operations.
Investor Verification Checklist
- Verify the status of the 30-month FDA stays for Lupin and Teva ANDAs and any potential court rulings that could shorten these periods.
- Confirm the filing date of the patent infringement lawsuit against Chemo Research S.L. to ensure the 30-month stay is triggered.
- Review the J.P. Morgan Healthcare Conference presentation (Exhibit 99.1) for detailed clinical data on vadadustat.
- Monitor future 10-Q and 10-K filings for updates on additional Paragraph IV certification notices and litigation outcomes.